Joe Y Chang

Particle Therapy Co-operative Group's Annual Meeting scientific program co-chair meeting was held in Houston. We received a historically high number of abstract submissions and selected the oral presentations and research award winners. Looking forward to seeing you in Normandy, France, 6/8-6/13.

5-20 brain mets, SRS improved quality of life as compared with HA-WBRT.

We’re thrilled to welcome @JoeChangMD, a thoracic radiation oncologist, to the #TexasLung26 faculty—joining 100+ experts in lung cancer. Be there in Austin, TX, Apr 9–11. Register FREE with code FREECME. View the full faculty ➜ na2.hubs.ly/H030sps0 #LungCancer #ThoracicOncology #Oncology #CME

On my last clinic day of 2025, I am DOD for SBRT, serving as the physician for the thoracic consultation clinic and covering emergency Radiation Oncology at MD Anderson. Holidays are always very challenging for our patients because cancer doesn’t take a vacation. From my 23 years of practice, I have learned that my best teachers are my patients. They have taught me how to maintain hope in the face of a "non-curable" diagnosis. When they supported my hesitation with trusting eyes and clasped hands, I felt re-energized. And when I could report "No evidence of disease," the joy radiating from their faces gave me the most profound understanding of life’s value and success. Happy New Year to you all!

The best part I love about the International Association for the Study of Lung Cancer (IASLC) is its truly global and multidisciplinary team. After two days of the Board of Directors meeting, eight of us attended a farewell dinner. We come from six countries across America, Europe, and Asia, with specialties in medical oncology, surgery, radiation oncology, translational research, and pulmonary medicine.@IASLC

Congratulations to the head and neck team who takes the lead to report overall survival benefit for proton therapy in Lancet. It is our responsibility to further improve radiation therapy technology and help our patients.

The 2026 Texas Lung Cancer Conference website is up with faculty & agenda. Join my co-chair, Dr. Tina Cascone, and me with 100+ expert faculty on April 9-11, 2026 at Austin City Limits for all the lung cancer updates you need! #TexasLung26 @TLCconference thetlcconference.com

📊 10-year STARS trial results: SABR is noninferior to VATS surgery for pts with operable early-stage NSCLC #LCSM ✔ Similar long-term OS ✔ Far fewer short-term complications (1% vs 50%) ✔ Strong noninvasive option for select patients 👨‍⚕️ @JoeChangMD 🔗 ascopost.com/issues/novembe…

During our lunch break at the clinic this Thursday, I want to extend my heartfelt thanks to our outstanding clinical team for their incredible support and effort. I wish each of you a happy holiday season!

MD Anderson boot walk to end cancer today. It is the 10th anniversary, and I am proud to be part of the team. There are more than 11,000 attendees today, and we raised about 2 million dollars for cancer research.

MDT management is the standard of care for early-stage lung cancer and improves survival.

Alarming facts for oncology community, patients and funding agencies. How should we conquer cancer by supporting more research for curative treatments.

In my view, you should consider PSA screen as long as your life expectancy is >15 years. My parents are 95 years old and still “healthy”. I will not stop screen until older than 80. Individualized cancer screening is needed.

@rweichselbaum We were very nice to each others. He is a quiet gentleman.

@JoeChangMD I hope you were nice to him😊

In honor of compassionate work of my esteemed colleague, Dr. Louis Pisters, acknowledge his inspiring message and amazing accomplishments in international missions. He was my lab “neighbor” when he was Urology fellow and I was Thoracic Surgery research fellow at MDACC in 1993.

Brilliant work by rad onc resident @adam_grippin @MDAndersonNews

PD-1 >=50% is a very strong indicator for immunotherapy. No chemo needed is confirmed.

A press release summarizes what I thought was the most important lung cancer abstract presented at #ASTRO25. It represents the updated REVISED STARS study results from MDACC. astro.org/news-and-publi…

@tnewsomdavis @_ShankarSiva @peters_solange @Mat_Guc @piet_ost @drdavidpalma @DrewMoghanaki @PercyLeeMD @rweichselbaum @DrJNaidoo @gerryhanna Although OS as the primary endpoint is more solid, it is, however, not practical since significant pts, who progressed, received local therapies eventually in the control arm.

@_ShankarSiva @peters_solange @Mat_Guc @piet_ost @drdavidpalma @DrewMoghanaki @PercyLeeMD @rweichselbaum @DrJNaidoo @gerryhanna @JoeChangMD Really interesting study and an important area. But I struggle with PFS as an endpoint in a situation where all relevant bits have just been irradiated / resected. OS will be more important metric. But also wonder if we need a new endpoint to describe outcome of LCT trials.

📣 #ESMO25: NORTHSTAR RCT @YasirElaminMD; n=120 EGFR-mut #lungcancer osimertinib +/- LCT (68% #radiotherapy) ⬆️ 12-month PFS rate: 72% vs 54% ⬆️ PFS (25.3 vs 17.5 mo; HR 0.66; P=0.025) 😳 really not “oligo” population! ✅Grade ≥3 AEs: 29% (LCT arm) vs 22% (control) #radonc